TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22301077

Group type: EXPERIMENTAL
Intervention: Antidepressant use (SSRIs and TCAs)
Number of subjects: 6998

Group type: EXPERIMENTAL
Intervention: Depressed users of antidepressants
Number of subjects: 6998

Group type: EXPERIMENTAL
Intervention: Non-depressed users of antidepressants
Number of subjects: 6998

Group type: EXPERIMENTAL
Intervention: Depressed non-users of antidepressants
Number of subjects: 6998

Group type: COMPARATOR
Intervention: All three groups (depressed users, non-depressed users, depressed non-users)
Number of subjects: 6998
Study: 20236108

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted radical vaginal hysterectomy (LARVH)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Radical abdominal hysterectomy (RAH)
Number of subjects: 15
Study: 18343254

Group type: EXPERIMENTAL
Intervention: Propofol 4 mg/kg i.v. followed by infusion of 150 microg/kg x min(‐1)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sevoflurane 8% by face mask followed by sevoflurane 1.5%
Number of subjects: 88
Study: 15839438

Group type: EXPERIMENTAL
Intervention: Leukocyte-Inhibition-Module (LIM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no LIM)
Number of subjects: 14
Study: 12417881

Group type: EXPERIMENTAL
Intervention: anti-IgE + SIT-grass (n = 23)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: anti-IgE + SIT-birch (n = 23)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: anti-IgE + SIT-grass
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: anti-IgE + SIT-birch
Number of subjects: 92
Study: 10754735

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t-PA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: No thrombolytic therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (clinically healthy individuals)
Number of subjects: 44
Study: 8815395

Group type: EXPERIMENTAL
Intervention: High-dose thiamine supplementation (100 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1507325

Group type: EXPERIMENTAL
Intervention: Cystoscopically placed cobra catheter for directed irrigation during ESWL
Number of subjects: 45

Group type: COMPARATOR
Intervention: Randomly selected controls (no cobra catheter)
Number of subjects: 45
Study: 6436874

Group type: EXPERIMENTAL
Intervention: Single night-time dose of trazodone (100-400 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Divided daily doses of trazodone (100-400 mg)
Number of subjects: 56
Study: 31425658

Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care Control Condition
Number of subjects: 0
Study: 28853228

Group type: EXPERIMENTAL
Intervention: 200 mg/day Anagliptin (ANA) for 24 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 200 mg/day Anagliptin (ANA) for 12 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: 25 mg/day Alogliptin (ALO) for 24 weeks
Number of subjects: 87
Study: 26458536

Group type: EXPERIMENTAL
Intervention: Combination uridine triphosphate (UTP), cytidine monophosphate (CMP), and hydroxycobalamin (vitamin B12)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1435847

Group type: EXPERIMENTAL
Intervention: 1% ketoconazole shampoo
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 22614767

Group type: EXPERIMENTAL
Intervention: Hypertonic saline 5% (HS) (n = 16)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline (NS) (n = 25)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 20116296

Group type: EXPERIMENTAL
Intervention: HIV risk reduction program (four 2-hour sessions at community-based locations)
Number of subjects: 744
Study: 18332159

Group type: EXPERIMENTAL
Intervention: Lowest third of Vo(2max)
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Middle third of Vo(2max)
Number of subjects: 1347
Study: 15758755

Group type: EXPERIMENTAL
Intervention: Darifenacin (30 mg once daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 12724019

Group type: EXPERIMENTAL
Intervention: Metformin therapy (500 mg three times a day for 8 weeks)
Number of subjects: 40
Study: 10593775

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (2 L/min by nasal cannula)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nasal CPAP therapy (9 +/- 0.3 cm H(2)O)
Number of subjects: 25
Study: 8726183

Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy (29 patients)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Radiation therapy followed by surgery and chemotherapy (21 patients)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Surgery alone (25 patients)
Number of subjects: 75
Study: 2069188

Group type: EXPERIMENTAL
Intervention: Acoustic reflex testing using sinusoidal bursts of 125, 500, 1,000, and 2,000 Hz stimuli
Number of subjects: 21
Study: 6150185

Group type: EXPERIMENTAL
Intervention: Various scavengers of free radicals of the oxygen species
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dithranol (anthralin)
Number of subjects: 0
Study: 31908843

Group type: EXPERIMENTAL
Intervention: Abatacept in combination with methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in combination with methotrexate
Number of subjects: 0
Study: 30184096

Group type: EXPERIMENTAL
Intervention: Education + Self‐Regulation intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Education Only condition
Number of subjects: 54
Study: 26723110

Group type: EXPERIMENTAL
Intervention: Long interval (6 to 8 weeks) between neoadjuvant radiation therapy and surgery
Number of subjects: 210

Group type: COMPARATOR
Intervention: Short interval (2 weeks) between neoadjuvant radiation therapy and surgery
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Long interval (6 to 8 weeks)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Short interval (2 weeks)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study: 23263694

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention program including comprehensive ergonomic training, two interactive sessions, an ergonomic training brochure, and workplace visits with workstation adjustments.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention program
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no ergonomic intervention)
Number of subjects: 94
Study: 22267768

Group type: EXPERIMENTAL
Intervention: AZD9668 (60 mg twice daily orally for 4 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: AZD9668
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 56
Study: 20874829

Group type: EXPERIMENTAL
Intervention: Astra Tech® implants (n=24)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Brånemark® implants (n=23)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both implant systems
Number of subjects: 18
Study: 17696673

Group type: EXPERIMENTAL
Intervention: 16-week cognitive-behavioral group
Number of subjects: 91

Group type: COMPARATOR
Intervention: 16-week supportive/exploratory group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 91
Study: 17979957

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team care in community hospitals
Number of subjects: 490

Group type: COMPARATOR
Intervention: General hospital care
Number of subjects: 490
Study: 15526837

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study: 11225459

Group type: EXPERIMENTAL
Intervention: 0.2% Lavasept solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 80
Study: 9311442

Group type: EXPERIMENTAL
Intervention: ACR-CH (aclarubicin adsorbed on activated carbon particles)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ACR-AQ (aclarubicin aqueous solution)
Number of subjects: 30
Study: 8055500

Group type: EXPERIMENTAL
Intervention: Counter-rotational toothbrush (INTERPLAK Home Plaque‐Removal Instrument)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 32
Study: 3522311

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1800 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31196113

Group type: EXPERIMENTAL
Intervention: Thawed frozen embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 0
Study: 28097356

Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 683

Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 683
Study: 25856450

Group type: EXPERIMENTAL
Intervention: Weekly or biweekly visits from an educator
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-services only
Number of subjects: 0
Study: 24117970

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma
Number of subjects: 2168

Group type: COMPARATOR
Intervention: Well-controlled asthma
Number of subjects: 2168
Study: 21390976

Group type: EXPERIMENTAL
Intervention: Focused meditation with eye-closure technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focused meditation with context reinstatement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Context reinstatement
Number of subjects: 0
Study: 20026533

Group type: EXPERIMENTAL
Intervention: Figure-of-8 suturing
Number of subjects: 195

Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 195
Study: 17087951

Group type: COMPARATOR
Intervention: Adefovir dipivoxil 10 mg once daily for 48 weeks, followed by adefovir dipivoxil from week 49 to 96, and then open-label for up to 240 weeks.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil treatment for up to 240 weeks.
Number of subjects: 125
Study: 15008726

Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT) and Transurethral resection of the prostate (TURP)
Number of subjects: 146
Study: 11123371

Group type: EXPERIMENTAL
Intervention: TTS‐S patch + 0.6 mg of scopolamine per os (p.o.)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TTS‐S patch + 0.3 mg of scopolamine p.o.
Number of subjects: 25

Group type: COMPARATOR
Intervention: TTS‐S patch + placebo tablet
Number of subjects: 25
Study: 9678812

Group type: EXPERIMENTAL
Intervention: RBC 400 mg plus clarithromycin 250 mg and tinidazole 500 mg (RBCCT)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: RBC 400 mg plus clarithromycin 500 mg and amoxycillin 1 g (RBCCA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: RBC 400 mg plus tinidazole 500 mg and amoxycillin 1 g (RBCTA)
Number of subjects: 157
Study: 8205581

Group type: EXPERIMENTAL
Intervention: Colgate Platinum Professional Toothwhitening System
Number of subjects: 38

Group type: COMPARATOR
Intervention: Rembrandt Lighten Bleaching Gel
Number of subjects: 38
Study: 2645466

Group type: EXPERIMENTAL
Intervention: Immunotherapy (oral bacille Calmette‐Guérin [BCG] 120 mg once a month for 5 years)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (oral BCG 120 mg once a month for 5 years with meCCNU 130 mg/m2 on day 1 and 5-FU 325 mg/m2/day on days 1-5 and 375 mg/m2/day on days 36-40, repeated every 10 weeks for 8 cycles)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control (no further therapy after surgery)
Number of subjects: 253
Study: 31586257

Group type: EXPERIMENTAL
Intervention: Personalised transportable folding device for seating (DATP), used for 1 month after training course on seating.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group without device (D-).
Number of subjects: 56
Study: 30339194

Group type: EXPERIMENTAL
Intervention: ramucirumab+FOLFIRI
Number of subjects: 1072
Study: 28103611

Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg daily during a 12-week lead-in
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 77
Study: 25855679

Group type: EXPERIMENTAL
Intervention: No/Trace TR (n=167)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Mild TR (n=205)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Moderate TR (n=117)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Severe TR (n=18)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Severe TR
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Moderate TR
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Right atrial and RV enlargement
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: RV dysfunction
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Interaction between TR and mitral regurgitation severity
Number of subjects: 542
Study: 22592176

Group type: EXPERIMENTAL
Intervention: Handled medicine ball (HMB) throws included in the regular tennis practice
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overweighted racket (OWR) during regular tennis practice
Number of subjects: 44

Group type: COMPARATOR
Intervention: Regular tennis training (RTT)
Number of subjects: 44
Study: 21757667

Group type: EXPERIMENTAL
Intervention: Intravenous tissue-type plasminogen activator (tPA) at a total dose of 0.9 mg/kg, with 10% given as a 1-minute bolus and the remainder over 1 hour
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 8
Study: 19728370

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg
Number of subjects: 294
Study: 16752076

Group type: EXPERIMENTAL
Intervention: High telomere content (TC >123% of standard)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Low telomere content (TC <101% of standard)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves using TC thresholds
Number of subjects: 210
Study: 15146393

Group type: EXPERIMENTAL
Intervention: Psychotherapy initiation
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Psychotherapy completion
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Improvement in psychopathology
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Improvement in interpersonal problems
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Subjective experience of symptoms
Number of subjects: 140

Group type: COMPARATOR
Intervention: Psychotherapy outcome comparison
Number of subjects: 140
Study: 11713616

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9429271

Group type: EXPERIMENTAL
Intervention: Automated off-line AMMA-signal analysis system using selected features extracted from input data
Number of subjects: 11

Group type: COMPARATOR
Intervention: Artificial neural network method
Number of subjects: 11
Study: 8508462

Group type: COMPARATOR
Intervention: Sabeluzole 2 x 10 mg/d
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sabeluzole 3 x 10 mg/d
Number of subjects: 56
Study: 2832178

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus 600 cGy of both upper and lower half-body irradiation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 96
Study: 29668918

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study: 28034967

Group type: EXPERIMENTAL
Intervention: Online interactive continuing education (CE) program for primary care providers (PCPs)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control condition (online, text‐based CE program)
Number of subjects: 238
Study: 25557468

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (pre-CRT) followed by esophagectomy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: FDG-PET scan after pre-CRT
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ΔSUV
Number of subjects: 49
Study: 23060625

Group type: EXPERIMENTAL
Intervention: rhAPC via intrabronchial instillation
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 12
Study: 21198719

Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg once per day (group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice per day (group II)
Number of subjects: 30
Study: 17350868

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (fluticasone propionate 200 mcg/day by metered dose inhaler/spacer combination)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (fluticasone propionate)
Number of subjects: 96
Study: 16427167

Group type: EXPERIMENTAL
Intervention: Toronto Western Spasmodic Torticollis Rating Scale
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Electrogoniometry
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Toronto severity score
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lateral bending and rotation velocities
Number of subjects: 19
Study: 14563543

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 382
Study: 10851830

Group type: EXPERIMENTAL
Intervention: IL‐4
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IL‐10
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IL‐2
Number of subjects: 42

Group type: COMPARATOR
Intervention: TNF alpha
Number of subjects: 42
Study: 9351742

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation (30 ppm)
Number of subjects: 15
Study: 7713205

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training combined with cycle ergometer training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cycle ergometer training alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both training regimens
Number of subjects: 42
Study: 2455106

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 12
Study: 31498109

Group type: COMPARATOR
Intervention: efavirenz-based ART
Number of subjects: 74

Group type: COMPARATOR
Intervention: ritonavir-boosted atazanavir-based ART
Number of subjects: 74

Group type: COMPARATOR
Intervention: efavirenz or atazanavir
Number of subjects: 74
Study: 29071968

Group type: EXPERIMENTAL
Intervention: Vitalstim electroacupuncture (EA) combined with swallowing rehabilitation training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular medication and swallowing function rehabilitation training
Number of subjects: 80
Study: 26645524

Group type: EXPERIMENTAL
Intervention: Ginger essence inhalation (2 drops on gauze, repeated every 30 min for 2 hours)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ginger essence inhalation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study: 23516249

Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR® SN60D3 MIOL and Corneal® ACPI 11 CTR (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: AcrySof ReSTOR® SN60D3 MIOL without CTR (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 1 (with CTR)
Number of subjects: 60
Study: 21517667

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH), tinzaparin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 96
Study: 18284511

Group type: EXPERIMENTAL
Intervention: 0.05% Clobetasol + 2.5% zinc sulphate cream
Number of subjects: 47

Group type: COMPARATOR
Intervention: 0.05% Clobetasol alone cream
Number of subjects: 47
Study: 16585455

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 522

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 522
Study: 12728112

Group type: EXPERIMENTAL
Intervention: Naturopathic Herbal Extract Ear Drops (NHED) 5 drops 3 times daily
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Naturopathic Herbal Extract Ear Drops (NHED) with topical anesthetic 5 drops 3 times daily
Number of subjects: 171

Group type: COMPARATOR
Intervention: Topical anesthetic 5 drops 3 times daily
Number of subjects: 171

Group type: COMPARATOR
Intervention: Oral amoxicillin 80 mg/kg/d (maximum 500 mg/dose) divided into 3 doses with either NHED or topical anesthetic
Number of subjects: 171
Study: 12940661

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of recombinant tissue plasminogen activator (3 mg in 3 mL diluted into 250 mL of physiological saline solution, given every 12 hours)
Number of subjects: 27
Study: 10553534

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/day for 3 months
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/day for 6 months
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no cilostazol)
Number of subjects: 103
Study: 8909673

Group type: EXPERIMENTAL
Intervention: Full disclosure
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard disclosure (leaflet)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Minimal disclosure
Number of subjects: 45
Study: 1905501

Group type: EXPERIMENTAL
Intervention: Misoprostol, 200 micrograms four times a day
Number of subjects: 253

Group type: COMPARATOR
Intervention: Sucralfate, 1 g four times a day
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Comparison of Misoprostol vs Sucralfate
Number of subjects: 253
Study: 6359843

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3536631

Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring (EFM)
Number of subjects: 969

Group type: COMPARATOR
Intervention: AUS (stethoscope monitoring)
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Both methods (AUS and EFM)
Number of subjects: 969
Study: 29298077

Group type: EXPERIMENTAL
Intervention: Gabapentin only (900 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine (OMM) only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gabapentin plus OMM
Number of subjects: 40
Study: 29078965

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (standardized needle manipulation at LI10 and LI11 for 2 minutes)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mock laser control (inactive laser at LI10 and LI11 for 2 minutes)
Number of subjects: 96